Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

SZSE:300357 Rapporto sulle azioni

Cap. di mercato: CN¥10.0b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Wolwo Bio-Pharmaceutical Crescita futura

Future criteri di controllo 5/6

Zhejiang Wolwo Bio-Pharmaceutical is forecast to grow earnings and revenue by 22.8% and 21.2% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 16.8% in 3 years.

Informazioni chiave

22.8%

Tasso di crescita degli utili

22.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili18.8%
Tasso di crescita dei ricavi21.2%
Rendimento futuro del capitale proprio16.8%
Copertura analitica

Low

Ultimo aggiornamento10 Jun 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Jun 30
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

May 27
Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

May 07
Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Mar 22
Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Previsioni di crescita degli utili e dei ricavi

SZSE:300357 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20261,5825994195323
12/31/20251,3094932984684
12/31/20241,0453901653033
3/31/2024881317145342N/A
12/31/2023848310155382N/A
9/30/2023870292117362N/A
6/30/202389331674358N/A
3/31/2023882328139389N/A
1/1/2023896349160360N/A
9/30/2022888391199369N/A
6/30/2022849372268385N/A
3/31/2022841359183316N/A
12/31/2021808338236361N/A
9/30/2021765324200307N/A
6/30/2021724319183276N/A
3/31/2021691308218288N/A
12/31/2020636278186256N/A
9/30/2020630281183267N/A
6/30/2020624275155251N/A
3/31/2020612274142252N/A
12/31/2019639298129233N/A
9/30/2019615290120232N/A
6/30/2019556259134227N/A
3/31/2019532247124197N/A
12/31/2018501233144206N/A
9/30/2018478227137173N/A
6/30/2018439211142169N/A
3/31/2018411200149178N/A
12/31/2017386186N/A159N/A
9/30/2017367175N/A150N/A
6/30/2017344154N/A137N/A
3/31/2017324139N/A128N/A
12/31/2016312129N/A123N/A
9/30/2016303129N/A127N/A
6/30/2016283121N/A116N/A
3/31/2016277122N/A121N/A
12/31/2015267118N/A115N/A
9/30/2015261116N/A107N/A
6/30/2015252112N/A110N/A
3/31/2015247110N/A101N/A
12/31/2014240100N/A84N/A
9/30/201422890N/A75N/A
6/30/201421178N/A62N/A
3/31/201420268N/A59N/A
12/31/201319471N/A58N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: 300357's forecast earnings growth (22.8% per year) is above the savings rate (2.9%).

Guadagni vs Mercato: 300357's earnings (22.8% per year) are forecast to grow faster than the CN market (21.9% per year).

Guadagni ad alta crescita: 300357's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: 300357's revenue (21.2% per year) is forecast to grow faster than the CN market (13.4% per year).

Ricavi ad alta crescita: 300357's revenue (21.2% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: 300357's Return on Equity is forecast to be low in 3 years time (16.8%).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y